成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Carfilzomib

Carfilzomib Struktur
868540-17-4
CAS-Nr.
868540-17-4
Englisch Name:
Carfilzomib
Synonyma:
PR 171;CS-603;Carfezomil;Carfilzomib;PR171;PR 171;Carfilzomib API;CarfilzoMib salt;CarfilzoMib/PR 171;Carfilzomib, >=99%;PR-171 (CarfilzoMib)
CBNumber:
CB12520831
Summenformel:
C40H57N5O7
Molgewicht:
719.92
MOL-Datei:
868540-17-4.mol

Carfilzomib Eigenschaften

Schmelzpunkt:
204 - 208°C
Siedepunkt:
975.6±65.0 °C(Predicted)
Dichte
1.161
Flammpunkt:
543.8℃
storage temp. 
-20°
L?slichkeit
Soluble in DMSO (up to 80 mg/ml) or in Ethanol (up to 25 mg/ml).
Aggregatzustand
solid
pka
13.17±0.46(Predicted)
Farbe
White
Stabilit?t:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 week.
CAS Datenbank
868540-17-4
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
HS Code  29337900
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitssch?dlich bei Verschlucken. Akute Toxizit?t oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizit?t (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.

Carfilzomib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In July 2012, the US FDA approved carfilzomib (also referred to as PR-171) for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression within 60 days of completion of the last therapy. Carfilzomib binds to and irreversibly inhibits the chymotrypsin-like protease activity of the constitutive proteosome (β5) and immunoproteosome (β5i) via its epoxyketone pharmacophore. Proteosome inhibition results in the accumulation of polyubiquitinated proteins and induction of apoptosis through activation of both the intrinsic and extrinsic caspase pathways. Carfilzomib inhibits chymotrypsin activity with an IC50 of 6 nM and is less potent an inhibitor of trypsin and caspase (IC50s of 3600 and 2400 nM, respectively). Cell cycle arrest and apoptosis are seen in a variety of hematologic and solid tumor cell lines (e.g.,MM, acutemyeloid leukemia (AML), pancreatic cancer, lung cancer) treated with carfilzomib.

Chemische Eigenschaften

White Solid

Verwenden

Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.

Definition

ChEBI: Carfilzomib is a synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2<element S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma.

Clinical Use

Carfilzomib is an irreversible inhibitor of the chymotrypsin-like protease in the proteasome and was approved in the U.S. for the treatment of multiple myeloma. Carfilzomib was discovered by Proteolix which was later acquired by Onyx Therapeutics who completed the development of this drug. Carfilzomib is also undergoing clinical evaluation for additional oncology indications such as relapsed solid tumors, lymphoma, prolymphocytic leukemia, acute myeloid leukemia and acute lymphocytic leukemia.

Carfilzomib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Carfilzomib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 352)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 997 58
Hangzhou Hyper Chemicals Limited
+86-0086-57187702781 +8613675893055
info@hyper-chem.com China 295 58
Alpha Biopharmaceuticals Co., Ltd
+86-15542445688
sales@alabiochem.com China 888 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21639 55
Chembon Pharmaceutical Co., Ltd.
+86-28-8425-2981
CHINA 722 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714
fandachem@gmail.com China 9218 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32820 60
Lianyungang happen teng technology co., LTD
15950718863
wang666xt@163.com CHINA 295 58
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29886 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 965 58

868540-17-4()Verwandte Suche:


  • CarfilzoMib salt
  • CarfilzoMib/PR 171
  • PR 171
  • PR-171 (CarfilzoMib)
  • (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • Carfilzomib
  • CarfilzoMib, Free Base, >99%
  • (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide
  • L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-
  • (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide Carfilzomib(PR171)
  • Carfilzomib (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • Carfilzomib, >=99%
  • (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • (S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo
  • N-{(2S)-2-[(Morpholin-4-ylacetyl)aMino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-Methyl-1-[(2R)-2-Methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninaMide
  • Carfilzomib API and intermediates
  • Carfilzomib, 99%, irreversible proteasome inhibitor
  • PR171;PR 171
  • CS-603
  • Carfilzomib API
  • Carfilzomib (2R,4S)-Diol (7R)-Isomer
  • Carfilzomib (2S,4S)-Diol (7R)-Isomer
  • Carfilzomib (2S,4R)-Diol (7R)-Isomer
  • Carfilzomib (2R,4R)-Diol (7R)-Isomer
  • (S)-4-Methyl-N-[(S)-1-[[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxo-2-pentyl]amino]-1-oxo-3-phenyl-2-propyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]pentanamide
  • 7(R)-epi Carfilzomib (2R,4S)-diolQ: What is 7(R)-epi Carfilzomib (2R,4S)-diol Q: What is the CAS Number of 7(R)-epi Carfilzomib (2R,4S)-diol
  • 7(R)-epi Carfilzomib (2S,4R)-diolQ: What is 7(R)-epi Carfilzomib (2S,4R)-diol Q: What is the CAS Number of 7(R)-epi Carfilzomib (2S,4R)-diol
  • L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]- (Carfilzomib impurity)
  • (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • Carfilzomib(For R & D only)
  • Carfezomil
  • 868540-17-4
  • 86854-17-4
  • C40H57N5O7
  • Inhibitors
  • peptides
  • API
  • Inhibitor
  • Pharmaceutical
  • 868540-17-4
  • Coronavirus
Copyright 2019 ? ChemicalBook. All rights reserved